Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
Letters1 January 2002Osteoarthritis: New InsightsDavid D. Waddell, MDDavid D. Waddell, MDLouisiana State University, Shreveport, LA 71103Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-1-200201010-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The authors of the review series on osteoarthritis (1) are to be commended for their effort to focus attention on advances in treatment and for their well-referenced, concise summary. Primary care providers need to become familiar with all options in order to offer comprehensive treatment programs. The omission of viscosupplementation, therefore, was surprising. The U.S. Food and Drug Administration approved hyaluronan-based viscosupplements in 1997 for the treatment of symptoms of knee osteoarthritis after failure of nonpharmacologic therapy and acetaminophen. Viscosupplements have been used clinically for osteoarthritis in Europe and Japan for over 10 years, and a high-molecular-weight ...References1. Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA, et al . Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med. 2000;133:726-37. [PMID: 11074906] LinkGoogle Scholar2. Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, et al . The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage. 1995;3:213-25. [PMID: 8689457] CrossrefMedlineGoogle Scholar3. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20:410-23. [PMID: 9663358] CrossrefMedlineGoogle Scholar4. Weiss C, Waddell D, Miller E. The availability of highly elastoviscous hylan for viscosupplementation can delay knee replacement in patients with advanced osteoarthritis. In: Kennedy JF, Phillips GO, Williams PA, Hascall VC, eds. Hyaluronan 2000. Cambridge: Woodhead; [In press]. Google Scholar5. Wobig M, Beks P, Dickhut A, Maier R, Vetter G. Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 (Synvisc) in primary osteoarthritis of the knee. J Clin Rheumatol. 1999;5 Suppl 6 S24-S31. Google Scholar Author, Article, and Disclosure InformationAuthors: David D. Waddell, MDAffiliations: Louisiana State University, Shreveport, LA 71103 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOsteoarthritis: New Insights. Part 2: Treatment Approaches Conference Chair: David T. Felson , Conference Organizer: Reva C. Lawrence , Discussants: Marc C. Hochberg , Timothy McAlindon , Paul A. Dieppe , Marian A. Minor , Steven N. Blair , Brian M. Berman , James F. Fries , Morris Weinberger , Kate R. Lorig , Joshua J. Jacobs , and Victor Goldberg Osteoarthritis: New Insights Paul J. Rosch Osteoarthritis: New Insights Robert H. Palmer Osteoarthritis: New Insights David T. Felson and Timothy McAlindon Osteoarthritis: New Insights Thomas E. Lindow Metrics 1 January 2002Volume 136, Issue 1Page: 86KeywordsArthroscopyClinical trialsDrugsFood and Drug AdministrationKneesNSAIDsOrthopedicsOsteoarthritis ePublished: 1 January 2002 Issue Published: 1 January 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it